Abstract:Background:: The increasing prevalence of depression has become a global health issue. Currently approved anti-depressive including 5-hydroxytryptamine (5-HT), dopamine (DA), norepinephrine (NE), triple reuptake inhibitors (TRIs) and glutamate N-methyl-D-aspartate (NMDA) receptor antagonists have limited effects because of their insufficient efficacy and/or slow onset of action. Developing multifunctional antidepressants that can modulate 5-HT, DA, NE, and NMDA simultaneously can potentially overcome the current drug defects. Objective:: This study aimed to explore leads for the development of multi-functional anti-depressive agents that simultaneous triple reuptake inhibitory and NMDA-GluN2B receptor antagonistic activities objective: This study aimed to explore leads for the development of multi-functional anti-depressive agents that simultaneous triple reuptake inhibitory and NMDA-GluN2B receptor antagonistic activities. Methods:: Potential leads were screened virtually from the TCMSP database based on the 3D-Pharmacophore model of TRIs followed by the molecular docking into NMDA-GluN2B receptor, BBB score, and the in-silico toxicity evaluation. The biological activities of discovered leads on 5-HT, NE, and DA reuptake and their effect on the NMDA-GluN2B receptor were evaluated via radio-labeled neurotransmitters and competition radio-ligand binding experiment with [3H] ifenprodil, respectively. Lastly, the antidepressant effect of these potential leads was determined in vivo through the forced swim test in mice Results:: Two compounds were attained as potential leads after the aforementioned experiments. Further in vitro biological evaluation identified Hit-2 as a promising lead that exerted favorable triple 5-HT/DA/NE reuptake inhibitory activity (66.98% inhibition rate at 10μM against hNET, 73.01% inhibition rate at 1μM against hDAT and 86.27% inhibition rate at 1μM against hSERT), as well as potent NMDA-GluN2B receptor antagonistic activity (Ki=115.73±3.54nM). The antidepressant activity of Hit-2 was confirmed through in vivo experiments Conclusion:: Hit-2 not only simultaneously inhibited the reuptake of 5-HT, DA, and NE, and acted as an NMDA-GluN2B receptor antagonist in vitro but also showed in vivo antidepressant activity. These findings may serve as a structural basis for the further development of multi-functional anti-depressive agents. other: none

New lead discovery for novel M1 agonists: pharmacophore model based on DISCO computation and virtual screening

Construction Of The Pharmacophore Models Of M-1 Receptor Agonists By Distance Comparison Method

Computational modeling toward understanding agonist binding on dopamine 3.

The optimization of a novel selective antagonist for human M<sub>2</sub> muscarinic acetylcholine receptor

Computational study on new natural compound agonists of dopamine receptor

Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach

Molecular Docking and Molecular Dynamics Simulation Studies of GPR40 Receptor–agonist Interactions

Novel Scaffold Agonists of the α2A Adrenergic Receptor Identified via Ensemble-Based Strategy

Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Synthesis and Pharmacological Characterization of 4-Substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: Identification of New Potent and Selective Metabotropic Glutamate 2/3 Receptor Agonists.

Discovery of Multiple Lead Compounds As M2 Inhibitors Through the Focused Screening of a Small Primary Amine Library

Comparative Pharmacophore Modeling of Human Adenosine Receptor A1 and A3 Antagonists

Discovery of Multi-Functional Lead Compounds Originating from Traditional Chinese Medicine for Developing Anti-Depressive Agents via Virtual Screening

X-ray Crystallography, DFT Calculations and Molecular Docking of Indole-Arylpiperazine Derivatives As Α1a-Adrenoceptor Antagonists

A Ligand-and-structure Dual-driven Deep Learning Method for the Discovery of Highly Potent GnRH1R Antagonist to treat Uterine Diseases

Higher-Affinity Agonists of 5-HT1AR Discovered Through Tuning the Binding-Site Flexibility

Discovery of Fused Heterocyclic Carboxamide Derivatives As Novel Α7-Nachr Agonists: Synthesis, Preliminary SAR and Biological Evaluation.

Fragment-Based Computational Method for Designing GPCR Ligands

Molecular Modeling of the 3D Structure of 5-HT(1A)R: Discovery of Novel 5-HT(1A)R Agonists Via Dynamic Pharmacophore-Based Virtual Screening.